[18F]-Fluorodeoxyglucose Positron Emission Tomography for In Vivo Assessment of Glucose Metabolism in Pheochromoctyoma and Paraganglioma

[18F]-Fluorodeoxyglucose Positron Emission Tomography for In Vivo Assessment of Glucose Metabolism in Pheochromoctyoma and Paraganglioma - GLUMEPP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38518

Enrollment

Registered

2013-09-10

Start date

2013-10-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adrenal tumours

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >= 18 years, no upper limit - Suspected diagnosis of benign PCC or PGL: 1. Biochemically proven by elevated plasma and/or urinary (nor)metanephrines 2. Anatomically substrate; localization of an (extra)-adrenal tumor by conventional anatomical (MRI/CT) imaging - Regardless of the genetic status (sporadic or hereditary) - Planned for surgical resection (adrenalectomy or extra-adrenal tumor resection) - Size tumor at least 1 cm in smallest diameter (as determined by conventional imaging)

Exclusion criteria

Exclusion criteria: - Malignant PPGL, i.e. presence of lesions on imaging studies suggestive of distant metastasis - No initial CT or MRI available - Contra-indication for surgery: o Based on (biological) age, cardiovascular risk factors, performance status or other co-morbidity as decided by a multidisciplinary team including medical endocrinologist, urologists, radiologists, pathologists and nuclear medicine physicians. - Contra-indication for dynamic FDG-PET/CT o Diabetes mellitus or fasted glucose level >= 8.0 mmol.L-1 o Pregnancy o Breast-feeding o Sever claustrophobia - Interval between dynamic FDG-PET/CT and surgery more than 60 days - Incapability to adhere to study protocol - Inability to give informed consent (e.g. psychiatric illness)

Design outcomes

Primary

Measure	Time frame
To increase insight in the in vivo glucose metabolism in PPGL by performing pharmacokinetic analyses of dynamic FDG-PET/CT scanning.	—

Secondary

Measure	Time frame
- To assess the genotypic specific differences in glucose metabolism across sporadic and hereditary PPGLs and to evaluate whether higher FDG-PET/CT SUV observed in SDHx and VHL-related PPGL is a reflection of an increased FDG uptake and/or metabolism as a reflection the Warburg effect. - To investigate whether quantitative dynamic FDG-PET/CT parameters correlate with tumor histology and tissue markers of glucose metabolism (GLUT-1, GLUT-3, HK-2, HK-3 and MCT-4) and vascularity (VEGF, CD34).	—

Measure

Time frame

- To assess the genotypic specific differences in glucose metabolism across sporadic and hereditary PPGLs and to evaluate whether higher FDG-PET/CT SUV observed in SDHx and VHL-related PPGL is a reflection of an increased FDG uptake and/or metabolism as a reflection the Warburg effect. - To investigate whether quantitative dynamic FDG-PET/CT parameters correlate with tumor histology and tissue markers of glucose metabolism (GLUT-1, GLUT-3, HK-2, HK-3 and MCT-4) and vascularity (VEGF, CD34).

—

Countries

Netherlands

Outcome results